Skip to main content


Generic name: cabotegravir
Dosage form: extended-release injectable suspension for intramuscular use
Drug class: Integrase strand transfer inhibitor

Medically reviewed by Judith Stewart, BPharm. Last updated on Jun 30, 2022.

What is Apretude?

Apretude is a prescription medicine used for HIV-1 PrEP to reduce the risk of getting HIV-1 infection in adults and adolescents who weigh at least 77 pounds (at least 35 kg).

HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).

It is not known if this medicine is safe and effective in children younger than 12 years of age or weighing less than 77 pounds (less than 35 kg).

Important information

Important information for people who receive Apretude to help reduce their risk of getting human immunodeficiency virus-1 (HIV-1) infection, also called pre exposure prophylaxis or “PrEP”:

Before receiving Apretude to reduce your risk of getting HIV-1:

  • You must be HIV-1 negative to start Apretude. You must get tested to make sure that you do not already have HIV-1 infection.
  • Do not receive Apretude for HIV-1 PrEP unless you are confirmed to be HIV-1 negative.
  • Some HIV-1 tests can miss HIV-1 infection in a person who has recently become infected. If you have flu-like symptoms, you could have recently become infected with HIV-1. Tell your healthcare provider if you had a flu-like illness within the last month before starting Apretude or at any time while receiving Apretude. Symptoms of new HIV-1 infection include:
    • tiredness
    • joint or muscle aches
    • sore throat
    • rash
    • enlarged lymph nodes in the neck or groin
    • fever
    • headache
    • vomiting or diarrhea
    • night sweats

While you are receiving Apretude for HIV-1 PrEP:

  • Apretude does not prevent other sexually transmitted infections. Practice safer sex by using a latex or polyurethane condom to reduce the risk of getting sexually transmitted infections.
  • You must stay HIV-1 negative to keep receiving Apretude for HIV-1 PrEP.
    • Know your HIV-1 status and the HIV-1 status of your partners.
    • Ask your partners with HIV-1 if they are taking anti-HIV-1 medicines and have an undetectable viral load. An undetectable viral load is when the amount of virus in the blood is too low to be measured in a lab test. To maintain an undetectable viral load, your partners must keep taking HIV-1 medicine as prescribed. Your risk of getting HIV-1 is lower if your partners with HIV-1 are taking effective treatment.
    • Get tested for HIV-1 with each Apretude injection or when your healthcare provider tells you. You should not miss any HIV-1 tests. If you become HIV-1 infected and continue receiving Apretude because you do not know you are HIV-1 infected, the HIV-1 infection may become harder to treat.
    • Get tested for other sexually transmitted infections such as syphilis, chlamydia, and gonorrhea. These infections make it easier for HIV-1 to infect you.
    • If you think you were exposed to HIV-1, tell your healthcare provider right away. They may want to do more tests to be sure you are still HIV-1 negative.
    • Get information and support to help reduce sexual risk behaviors.
    • Do not miss any injections of Apretude. Missing injections increases your risk of getting HIV-1 infection.
    • If you do become HIV-1 positive, you will need to take other medicines to treat HIV-1. Apretude is not approved for treatment of HIV-1.

If you have HIV-1 and receive only Apretude, over time your HIV-1 may become harder to treat.

Who should not receive Apretude?

You should not receive Apretude if you:

  • already have HIV-1 infection. If you are HIV-1 positive, you will need to take other medicines to treat HIV-1. Apretude is not approved for treatment of HIV-1.
  • do not know your HIV-1 infection status. You may already be HIV-1 positive. You need to take other medicines to treat HIV-1. Apretude can only help reduce your risk of getting HIV-1 infection before you are infected.
  • are allergic to cabotegravir

Before receiving Apretude

Before receiving Apretude, tell your healthcare provider about all your medical conditions, including if you:

  • have ever had a skin rash or an allergic reaction to medicines that contain cabotegravir.
  • have or have had liver problems.
  • have ever had mental health problems.
  • are pregnant or plan to become pregnant. It is not known if Apretude will harm your unborn baby. Apretude can remain in your body for up to 12 months or longer after the last injection. Tell your healthcare provider if you become pregnant while receiving Apretude.
    Pregnancy Registry. There is a pregnancy registry for women who receive Apretude during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.
  • are breastfeeding or plan to breastfeed. It is not known if Apretude can pass to your baby in your breast milk. Talk with your healthcare provider about the best way to feed your baby while receiving Apretude.

What other drugs will affect Apretude?

Tell your healthcare provider about all the medicines you take, including prescription and over-thecounter medicines, vitamins, and herbal supplements. Some medicines may interact with Apretude. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

You can ask your healthcare provider or pharmacist for a list of medicines that interact with Apretude.

Do not receive Apretude if you are taking any of the following medicines:

  • carbamazepine
  • oxcarbazepine
  • phenobarbital
  • phenytoin
  • rifampin
  • rifapentine

Do not start a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is safe to receive Apretude with other medicines.

How will I receive Apretude?

  • Apretude is initially given as an injection into the muscle of your buttock 1 time every month for the first 2 months, then as an injection 1 time every 2 months.
  • Before receiving your first injection dose of Apretude, your healthcare provider may have you take 1 oral cabotegravir tablet 1 time a day for 1 month (at least 28 days). This will allow your healthcare provider to assess how well you will tolerate cabotegravir.
  • Apretude is a long-acting medicine and may stay in your body for 12 months or longer after your last injection.
  • Stay under the care of a healthcare provider while receiving Apretude. It is important that you receive Apretude as scheduled.
  • If you miss or plan to miss a scheduled injection of Apretude by more than 7 days, call your healthcare provider right away to discuss your PrEP options.
  • If you stop receiving Apretude, talk to your healthcare provider about other options to reduce the risk of getting HIV-1 infection.

Dosage information

Usual Adult Dose for HIV-1 PrEP

- Initiate Apretude with a single 600-mg (3-mL) injection given 1 month apart for 2 consecutive months on the last day of an oral lead-in if used or within 3 days and continue with the injections every 2 months thereafter.

- Use: at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test prior to initiating Apretude (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP.

Apretude side effects

Apretude may cause serious side effects including:

  • Allergic reactions. Call your healthcare provider right away if you develop a rash with Apretude.
    Stop receiving Apretude and get medical help right away if you develop a rash with any of the following signs or symptoms:
    • fever
    • generally ill feeling
    • tiredness
    • muscle or joint aches
    • trouble breathing
    • blisters or sores in mouth
    • blisters
    • redness or swelling of the eyes
    • swelling of the mouth, face, lips, or tongue
  • Liver problems. Liver problems have happened in people with or without a history of liver problems or other risk factors. Your healthcare provider may do blood tests to check your liver function.

Call your healthcare provider right away if you develop any of the following signs or symptoms of liver problems:

    • your skin or the white part of your eyes turns yellow (jaundice)
    • dark or “tea-colored” urine
    • light-colored stools (bowel movements)
    • nausea or vomiting
    • loss of appetite
    • pain, aching, or tenderness on the right side of your stomach area
    • itching
  • Depression or mood changes. Call your healthcare provider or get medical help right away if you have any of the following symptoms:
    • feeling sad or hopeless
    • feeling anxious or restless
    • have thoughts of hurting yourself (suicide) or have tried to hurt yourself

The most common side effects include:

  • pain, tenderness, hardened mass or lump, swelling, bruising, redness, itching, warmth, loss of sensation at the injection site, abscess, and discoloration
  • diarrhea
  • headache
  • fever
  • tiredness
  • sleep problems
  • nausea
  • dizziness
  • passing gas
  • stomach pain
  • vomiting
  • muscle pain
  • rash
  • loss of appetite
  • drowsiness
  • back pain
  • upper respiratory infection

These are not all the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800 FDA1088.

General information about the safe and effective use of Apretude.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information that is written for health professionals.

What are the ingredients in Apretude?

Active ingredient: cabotegravir
Inactive ingredients: mannitol, polyethylene glycol (PEG) 3350, polysorbate 20, and Water for Injection.



A complete dose of Apretude requires 1 injection: 600 mg (3 mL) of cabotegravir.
Apretude is a suspension that does not need further dilution or reconstitution.
Apretude is for gluteal intramuscular use only.
Note: The ventrogluteal site is recommended.

Storage information

Store at 2°C to 25°C (36°F to 77°F). Exposure up to 30°C (86°F) permitted.
Do not freeze.
Prior to administration:

  • If the pack has been stored in the refrigerator, the vial should be brought to room temperature prior to administration (not to exceed 30°C [86°F]).
  • Once Apretude has been drawn into the syringe, the medication can remain in the syringe for up to 2 hours before injecting. The filled syringes should not be placed in the refrigerator. If the medicine remains in the syringe for more than 2 hours, the filled syringe and needle must be discarded.


1. Inspect the vial.

  • Check that the expiration date has not passed.
  • Inspect the vial immediately. If you can see foreign matter, do not use the product.
    Note: The vial has a brown tint to the glass.
    Do not use if the expiration date has passed.
  • If the pack has been stored in the refrigerator, allow the medication to come to room temperature.

2. Shake the vial vigorously.

  • Hold the vial firmly, and vigorously shake for a full 10 seconds.
  • Invert the vial and confirm the suspension is uniform. It should look uniform.
  • If the suspension is not uniform, shake the vial again.
  • It is also normal to see small air bubbles.

3. Remove the vial cap.

  • Remove the cap from the vial.
  • Wipe the rubber stopper with an alcohol wipe.
  • Do not allow anything to touch the rubber stopper after wiping it.

4. Peel open the vial adapter.

  • Peel off the paper backing from the vial adapter packaging.
    Note: Keep the adapter in place in its packaging for the next step.

5. Attach the vial adapter.

  • Press the vial adapter straight down onto the vial using the packaging, as shown. The vial adapter should snap securely into place.
  • When you are ready, lift off the vial adapter packaging as shown.

6. Prepare the syringe.

  • Remove the syringe from its packaging.
  • Draw 1 mL of air into the syringe. This will make it easier to draw up the medicine later.

7. Attach the syringe.

  • Hold the vial adapter and vial firmly, as shown.
  • Screw the syringe firmly onto the vial adapter.
  • Press the plunger all the way down to push the air into the vial.

8. Slowly draw up the dose.

  • Invert the syringe and vial and slowly withdraw as much of the medicine as possible into the syringe. There may be more medicine than the dose amount.

9. Unscrew the syringe.

  • Unscrew the syringe from the vial adapter, holding the vial adapter.
  • Keep the syringe upright to avoid leakage. Check that the suspension looks uniform and milky white.

10. Attach the needle and affix syringe label.

  • Peel open the needle packaging part way to expose the needle base.
  • Keeping the syringe upright, firmly twist the syringe onto the needle.
  • Remove the needle packaging from the needle.


11. Prepare the injection site.

  • Apretude must be administered to a gluteal site.  Select from the following areas for the injection:
    • Ventrogluteal (recommended)
    • Dorsogluteal (upper outer quadrant)
      Note: For gluteal intramuscular use only. Do not inject intravenously.

12. Remove the cap.

  • Fold the needle guard away from the needle.
    • Pull off the injection needle cap.

13. Remove extra liquid from the syringe.

  • Hold the syringe with the needle pointing up. Press the plunger to the 3-mL dosing mark to remove extra liquid and any air bubbles.
    Note: Clean the injection site with an alcohol wipe. Allow the skin to air dry before continuing.

14. Stretch the skin.

Use the z-track injection technique to minimize medicine leakage from the injection site.

  • Firmly drag the skin covering the injection site, displacing it by about an inch (2.5 cm).
  • Keep it held in this position for the injection.

15. Insert the needle.

  • Insert the needle to its full depth, or deep enough to reach the muscle.

16. Inject the dose of medicine.

  • Still holding the skin stretched – slowly press the plunger all the way down.
  • Ensure the syringe is empty.
  • Withdraw the needle and release the stretched skin immediately.

17. Assess the injection site.

  • Apply pressure to the injection site using a gauze pad.
  • A small bandage may be used if bleeding occurs.
    Do not massage the area.

18. Make the needle safe.

  • Fold the needle guard over the needle.
  • Gently apply pressure using a hard surfaceto lock the needle guard in place.
  • The needle guard will make a click when it locks.

After injection

19. Dispose safely.

  • Dispose of used needle, syringe, vial, and vial adapter according to local health and safety laws.

Questions and Answers

  1. If the pack has been stored in the refrigerator, is it safe to warm the vial up to room temperature more quickly?
    The vial should be brought to room temperature before you are ready to give the injection, but make sure the vial does not get above 30°C (86°F). Do not use any heating methods, other than using the warmth of your hands.
  2. How long can Apretude be left in the syringe?
    It is best to inject (room temperature) Apretude as soon as possible after drawing it up. However, Apretude can remain in the syringe for up to 2 hours before injecting. If the medicine remains in the syringe for more than 2 hours, the filled syringe and needle must be discarded.
  3. Why do I need to inject air into the vial?
    Injecting 1 mL of air into the vial makes it easier to draw up the medicine into the syringe. Without the air, some liquid may flow back into the vial unintentionally, leaving less medicine than intended in the syringe.
  4. Why is the ventrogluteal administration approach recommended?
    The ventrogluteal approach into the gluteus medius muscle is recommended because it is located away from major nerves and blood vessels. A dorsogluteal approach into the gluteus maximus muscle is acceptable, if preferred by the healthcare professional. The injection should not be administered in any other site.

Popular FAQ

Is Apretude an HIV drug?

Apretude (cabotegravir extended-release injection) is a long-acting injection for HIV pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Apretude is an integrase strand transfer inhibitor (INSTI) and works by preventing viral DNA from entering the genetic material of human immune cells (T-cells).

Who makes the Apretude drug?

Apretude (cabotegravir extended-release injection), a long-acting injection for HIV PrEP, is made by the pharmaceutical company ViiV Healthcare. In the U.S., ViiV Healthcare can be reached online or at 1-877-844-8872.

When did the FDA approve Apretude?

On December 20, 2021, the FDA approved Apretude (cabotegravir extended-release injection), a long acting injection used for HIV-1 pre-exposure prophylaxis (PrEP) to lower the risk of getting HIV-1 infection in adults and adolescents who weigh at least 77 pounds (35 kg). Check with your doctor about Apretude availability.

Does Apretude have insurance coverage?

Apretude is probably paid for by your insurance if you have coverage. Based on your medical plan, you might have to pay for a portion of the cost or you may have a $0 copay. The manufacturer, ViiV Healthcare, may offer financial assistance to eligible patients by calling 1-844-588-3288, M-F, 8AM - 11PM (ET).

Apretude (cabotegravir) extended-release injection is a long-acting pre-exposure prophylaxis (PrEP) prescription medicine used to prevent HIV infection in people at risk for sexually-acquired HIV exposure. Cabenuva (cabotegravir and rilpivirine) is also a long-acting injection but is used to treat (not prevent) HIV-1 infection. Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.